Literature DB >> 26341051

Role of mTOR in glioblastoma.

Zekeriya Duzgun1, Zuhal Eroglu1, Cigir Biray Avci1.   

Abstract

Mammalian target of rapamycin (mTOR), which is a member of the serine/threonine protein kinase family, is a protein complex that has a central role of cell growth and proliferation. mTOR emerges as a critical cell growth checkpoint on phosphoinositide 3-kinase (PI3K) signaling pathway. In this case mTOR has become an important therapeutic target for glioblastoma (GBM) that is one of the most deadly types of cancer. Various combination treatments including inhibition of mTOR may provide more significant results in the treatment of GBM. In addition to new mTOR targets, which may have a plant origin form, more potent mTOR inhibitors by utilizing the computational methodology may emerge as a hope for GBM therapy. In the future, a better understanding of the functional properties of mTORC2 with its potent effective inhibitors may help design more efficiently GBM treatment modalities.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain tumors; Glioblastoma; PI3K/AKT/mTOR pathway; mTOR signaling

Mesh:

Substances:

Year:  2015        PMID: 26341051     DOI: 10.1016/j.gene.2015.08.060

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  27 in total

Review 1.  Nutritional strategies to optimise cognitive function in the aging brain.

Authors:  Devin Wahl; Victoria C Cogger; Samantha M Solon-Biet; Rosilene V R Waern; Rahul Gokarn; Tamara Pulpitel; Rafael de Cabo; Mark P Mattson; David Raubenheimer; Stephen J Simpson; David G Le Couteur
Journal:  Ageing Res Rev       Date:  2016-06-26       Impact factor: 10.895

2.  Phosphatidylethanolamine-binding protein 4 promotes lung cancer cells proliferation and invasion via PI3K/Akt/mTOR axis.

Authors:  Guiping Yu; Bin Huang; Guoqiang Chen; Yedong Mi
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

3.  The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma.

Authors:  Xiang Xu; Jiadi Xu; Linda Knutsson; Jing Liu; Huanling Liu; Yuguo Li; Bachchu Lal; John Laterra; Dmitri Artemov; Guanshu Liu; Peter C M van Zijl; Kannie W Y Chan
Journal:  Magn Reson Med       Date:  2019-02-22       Impact factor: 4.668

Review 4.  Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Authors:  Gulten Tuncel; Rasime Kalkan
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

Review 5.  RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.

Authors:  Mark A Weinberg
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

6.  microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells.

Authors:  Yan Cui; Jizong Zhao; Lei Yi; Yugang Jiang
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

7.  The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.

Authors:  Peng-Hsu Chen; Chia-Hsiung Cheng; Chwen-Ming Shih; Kuo-Hao Ho; Cheng-Wei Lin; Chin-Cheng Lee; Ann-Jeng Liu; Cheng-Kuei Chang; Ku-Chung Chen
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

Review 8.  Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications.

Authors:  Silvia Anahi Valdés-Rives; Diana Casique-Aguirre; Liliana Germán-Castelán; Marco A Velasco-Velázquez; Aliesha González-Arenas
Journal:  Biomed Res Int       Date:  2017-11-12       Impact factor: 3.411

Review 9.  Metabolic Reprogramming in Glioma.

Authors:  Marie Strickland; Elizabeth A Stoll
Journal:  Front Cell Dev Biol       Date:  2017-04-26

10.  Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.

Authors:  Maria Tsoli; Jie Liu; Laura Franshaw; Han Shen; Cecilia Cheng; MoonSun Jung; Swapna Joshi; Anahid Ehteda; Aaminah Khan; Angel Montero-Carcabosso; Pierre J Dilda; Philip Hogg; David S Ziegler
Journal:  Oncotarget       Date:  2018-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.